Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma

Kristen Detweiler-Short, Suzanne Hayman, Morie Gertz, Martha Lacy, Angela Dispenzieri, Shaji K Kumar, Steven R. Zeldenrust, Stephen J Russell, John A. Lust, Robert A. Kyle, Philip R. Greipp, Thomas Elmer Witzig, S Vincent Rajkumar

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

We report the long-term follow-up results of a phase II trial of thalidomide for early-stage multiple myeloma (MM). Patients were eligible if they had smoldering multiple myeloma (SMM) or indolent MM without the need for immediate therapy. Thalidomide was initiated at a dose of 200 mg/day and adjusted as tolerated. Disease progression was defined using modified American Society of Hematology/Food and Drug Administration consensus panel criteria for SMM. Thirty-one patients were enrolled; 29 (19 SMM and 10 indolent MM) were eligible. The median age was 61 years. Median follow-up of living patients was 10.2 years (range, 7.5-11.0 years). Ten patients (34%) had a partial response (PR) and nine had minimal response (MR) for an MR plus PR rate of 66%. The median time to progression (TTP) to symptomatic myeloma was 35 months. Median TTP was 61 months in those achieving PR, 39 months with MR, and 9 months among those failing to achieve either MR or PR, P 5 0.005. Median overall survival from diagnosis was 86 months; median survival from onset of symptomatic myeloma was 49 months. Grade 3-4 nonhematologic adverse events were noted in 55% of patients. Randomized trials are needed to determine the role of early therapy in SMM.

Original languageEnglish (US)
Pages (from-to)737-740
Number of pages4
JournalAmerican Journal of Hematology
Volume85
Issue number10
DOIs
StatePublished - 2010

Fingerprint

Thalidomide
Multiple Myeloma
Therapeutics
Survival
United States Food and Drug Administration
Secondary Prevention
Disease Progression

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. / Detweiler-Short, Kristen; Hayman, Suzanne; Gertz, Morie; Lacy, Martha; Dispenzieri, Angela; Kumar, Shaji K; Zeldenrust, Steven R.; Russell, Stephen J; Lust, John A.; Kyle, Robert A.; Greipp, Philip R.; Witzig, Thomas Elmer; Rajkumar, S Vincent.

In: American Journal of Hematology, Vol. 85, No. 10, 2010, p. 737-740.

Research output: Contribution to journalArticle

@article{57ecbc055cdf4362a2d8f5ced4850da1,
title = "Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma",
abstract = "We report the long-term follow-up results of a phase II trial of thalidomide for early-stage multiple myeloma (MM). Patients were eligible if they had smoldering multiple myeloma (SMM) or indolent MM without the need for immediate therapy. Thalidomide was initiated at a dose of 200 mg/day and adjusted as tolerated. Disease progression was defined using modified American Society of Hematology/Food and Drug Administration consensus panel criteria for SMM. Thirty-one patients were enrolled; 29 (19 SMM and 10 indolent MM) were eligible. The median age was 61 years. Median follow-up of living patients was 10.2 years (range, 7.5-11.0 years). Ten patients (34{\%}) had a partial response (PR) and nine had minimal response (MR) for an MR plus PR rate of 66{\%}. The median time to progression (TTP) to symptomatic myeloma was 35 months. Median TTP was 61 months in those achieving PR, 39 months with MR, and 9 months among those failing to achieve either MR or PR, P 5 0.005. Median overall survival from diagnosis was 86 months; median survival from onset of symptomatic myeloma was 49 months. Grade 3-4 nonhematologic adverse events were noted in 55{\%} of patients. Randomized trials are needed to determine the role of early therapy in SMM.",
author = "Kristen Detweiler-Short and Suzanne Hayman and Morie Gertz and Martha Lacy and Angela Dispenzieri and Kumar, {Shaji K} and Zeldenrust, {Steven R.} and Russell, {Stephen J} and Lust, {John A.} and Kyle, {Robert A.} and Greipp, {Philip R.} and Witzig, {Thomas Elmer} and Rajkumar, {S Vincent}",
year = "2010",
doi = "10.1002/ajh.21821",
language = "English (US)",
volume = "85",
pages = "737--740",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma

AU - Detweiler-Short, Kristen

AU - Hayman, Suzanne

AU - Gertz, Morie

AU - Lacy, Martha

AU - Dispenzieri, Angela

AU - Kumar, Shaji K

AU - Zeldenrust, Steven R.

AU - Russell, Stephen J

AU - Lust, John A.

AU - Kyle, Robert A.

AU - Greipp, Philip R.

AU - Witzig, Thomas Elmer

AU - Rajkumar, S Vincent

PY - 2010

Y1 - 2010

N2 - We report the long-term follow-up results of a phase II trial of thalidomide for early-stage multiple myeloma (MM). Patients were eligible if they had smoldering multiple myeloma (SMM) or indolent MM without the need for immediate therapy. Thalidomide was initiated at a dose of 200 mg/day and adjusted as tolerated. Disease progression was defined using modified American Society of Hematology/Food and Drug Administration consensus panel criteria for SMM. Thirty-one patients were enrolled; 29 (19 SMM and 10 indolent MM) were eligible. The median age was 61 years. Median follow-up of living patients was 10.2 years (range, 7.5-11.0 years). Ten patients (34%) had a partial response (PR) and nine had minimal response (MR) for an MR plus PR rate of 66%. The median time to progression (TTP) to symptomatic myeloma was 35 months. Median TTP was 61 months in those achieving PR, 39 months with MR, and 9 months among those failing to achieve either MR or PR, P 5 0.005. Median overall survival from diagnosis was 86 months; median survival from onset of symptomatic myeloma was 49 months. Grade 3-4 nonhematologic adverse events were noted in 55% of patients. Randomized trials are needed to determine the role of early therapy in SMM.

AB - We report the long-term follow-up results of a phase II trial of thalidomide for early-stage multiple myeloma (MM). Patients were eligible if they had smoldering multiple myeloma (SMM) or indolent MM without the need for immediate therapy. Thalidomide was initiated at a dose of 200 mg/day and adjusted as tolerated. Disease progression was defined using modified American Society of Hematology/Food and Drug Administration consensus panel criteria for SMM. Thirty-one patients were enrolled; 29 (19 SMM and 10 indolent MM) were eligible. The median age was 61 years. Median follow-up of living patients was 10.2 years (range, 7.5-11.0 years). Ten patients (34%) had a partial response (PR) and nine had minimal response (MR) for an MR plus PR rate of 66%. The median time to progression (TTP) to symptomatic myeloma was 35 months. Median TTP was 61 months in those achieving PR, 39 months with MR, and 9 months among those failing to achieve either MR or PR, P 5 0.005. Median overall survival from diagnosis was 86 months; median survival from onset of symptomatic myeloma was 49 months. Grade 3-4 nonhematologic adverse events were noted in 55% of patients. Randomized trials are needed to determine the role of early therapy in SMM.

UR - http://www.scopus.com/inward/record.url?scp=77957666850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957666850&partnerID=8YFLogxK

U2 - 10.1002/ajh.21821

DO - 10.1002/ajh.21821

M3 - Article

C2 - 20730790

AN - SCOPUS:77957666850

VL - 85

SP - 737

EP - 740

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 10

ER -